Each vial contains 10, 20 or 60mg of highly pure Retatrutide.

Retatrutide is a next-generation metabolic peptide classified as a triple agonist because it activates three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). By engaging this broader range of receptors, Retatrutide has demonstrated greater potential for reducing body fat mass compared to earlier single or dual-agonist therapies such as Semaglutide.